AZD0186 / AstraZeneca - LARVOL DELTA

Efficacy of novel small molecule GLP-1 receptor agonist AZD0186 on glucose stimulated insulin secretion in obese, male non-human primates (EASD 2023) - "AZD0186 was evaluated in 3 dose groups 0.1, 0.25 and 0.7 mg/kg, positive control Danuglipron at 1 mg/kg and one group was treated with placebo. In response to the ivGTT, all three doses of AZD0186 induced an increase in the insulin AUC, Kg and decreased the glucose AUC in obese, dysmetabolic NHPs. The efficacy of AZD0186 achieved in this study supports further evaluation in human."

Clinical • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

A Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186 (clinicaltrials.gov) - P1 | N=31 | Terminated | Sponsor: AstraZeneca | N=72 ➔ 31 | Recruiting ➔ Terminated; The decision was based on the overall data profile obtained from this study which did not demonstrate sufficient differentiation to surpass the current standard of care.

Enrollment change • Trial termination • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186 (clinicaltrials.gov) - P1 | N=72 | Recruiting | Sponsor: AstraZeneca

New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus